Using exosomes to improve immunotherapy for brain tumors in children
Naturally Targeted Exosomal TLR7/8 Agonist for Immunotherapy of Medulloblastoma
This study is testing a new treatment for children with medulloblastoma, a type of brain cancer, by using tiny particles from immune cells to help the body’s immune system fight the tumor more effectively while aiming to reduce side effects from standard treatments.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-10790660 on NIH RePORTER |
What this research studies
This research focuses on developing a new immunotherapy approach for treating medulloblastoma, a type of brain cancer in children. The study aims to utilize exosomes, which are natural carriers derived from immune cells, to deliver a specific drug that activates the immune system against the tumor. By targeting tumor-associated macrophages, the therapy seeks to enhance the immune response while minimizing harmful side effects associated with traditional treatments. The goal is to improve survival rates and reduce long-term complications for affected children.
Who could benefit from this research
Good fit: Ideal candidates for this research are children diagnosed with medulloblastoma, particularly those with the Sonic Hedgehog subtype.
Not a fit: Patients with other types of brain tumors or those who are not eligible for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less toxic treatments for children with medulloblastoma.
How similar studies have performed: Previous research has shown promise in using exosomes for targeted drug delivery in cancer therapy, indicating potential success for this novel approach.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Kabanov, Alexander V — Univ of North Carolina Chapel Hill
- Study coordinator: Kabanov, Alexander V
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.